Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers

Emerging evidence suggests a role of receptor activator of nuclear factor κB (RANK)/RANK ligand (RANKL) signaling in breast cancer development. Lower osteoprotegerin (OPG) levels, the endogenous decoy receptor for RANKL which competes with RANK for binding of RANKL, has been reported among BRCA muta...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Odén, Lovisa, Akbari, Mohammad, Zaman, Tasnim, Singer, Christian F., Sun, Ping, Narod, Steven A., Salmena, Leonardo, Kotsopoulos, Joanne
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2016
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5349945/
https://ncbi.nlm.nih.gov/pubmed/27893411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13417
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia